Published in JAMA Neurol on November 01, 2013
MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology (2015) 1.74
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler (2014) 1.56
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol (2014) 1.53
Demographic and clinical features of neuromyelitis optica: A review. Mult Scler (2015) 1.14
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci (2015) 1.07
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun (2014) 1.01
Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurol Neuroimmunol Neuroinflamm (2016) 0.96
Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol (2015) 0.84
Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. J Neuroinflammation (2015) 0.78
The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study. PLoS One (2015) 0.76
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci (2016) 0.76
Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. J Neurol (2015) 0.75
Neuroimmunology: Aquaporin-4-antibody-seronegative neuromyelitis optica is less common than previously thought. Nat Rev Neurol (2013) 0.75
Differential Diagnosis of Acute Myelopathies: An Update. Clin Neuroradiol (2015) 0.75
Fulminant Acute Ascending Hemorrhagic Myelitis Treated with Eculizumab. Front Neurol (2017) 0.75
Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis (2010) 7.60
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol (2011) 6.77
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology (2014) 6.73
Open letter to prime minister David Cameron and health secretary Andrew Lansley. BMJ (2010) 4.52
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain (2010) 3.95
Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med (2010) 3.93
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology (2012) 3.67
Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain (2013) 3.22
Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol (2012) 3.12
Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol (2011) 2.98
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain (2008) 2.91
Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology (2013) 2.77
Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain (2002) 2.77
The anatomy of spatial neglect based on voxelwise statistical analysis: a study of 140 patients. Cereb Cortex (2004) 2.63
Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol (2010) 2.54
Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology (2013) 2.52
Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol (2008) 2.48
Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol (2013) 2.42
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol (2005) 2.37
Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry (2013) 2.33
Disease-relevant autoantibodies in first episode schizophrenia. J Neurol (2010) 2.33
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med (2007) 2.28
Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol (2009) 2.25
Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain (2006) 2.25
Anti-N-methyl-D-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. Crit Care Med (2010) 2.24
Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry (2012) 2.21
Thalamic neurodegeneration in multiple sclerosis. Ann Neurol (2002) 2.20
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain (2012) 2.17
Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry (2012) 2.15
N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol (2009) 2.03
Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol (2003) 2.02
Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol (2010) 1.99
C1q and tumor necrosis factor superfamily: modularity and versatility. Trends Immunol (2004) 1.98
GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet (2013) 1.91
Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain (2011) 1.89
Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol (2004) 1.89
Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science (2006) 1.88
Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry (2013) 1.83
Long-term observational study of sporadic inclusion body myositis. Brain (2011) 1.69
Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol (2003) 1.69
Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol (2012) 1.67
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain (2012) 1.65
Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci (2004) 1.62
Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J (2008) 1.61
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology (2004) 1.56
N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord (2013) 1.55
Posterior thalamic hemorrhage induces "pusher syndrome". Neurology (2005) 1.55
Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol (2012) 1.54
Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies. Clin Neurophysiol (2006) 1.54
Diffusion abnormality in Balo's concentric sclerosis: clues for the pathogenesis. Eur Neurol (2005) 1.50
Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1. J Neurol Neurosurg Psychiatry (2013) 1.50
Pilomotor seizures and status in non-paraneoplastic limbic encephalitis. Epileptic Disord (2005) 1.47
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol (2013) 1.47
An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature (2007) 1.46
Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. Am J Hum Genet (2012) 1.46
Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry (2012) 1.45
Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci (2010) 1.45
Exome sequencing can detect pathogenic mosaic mutations present at low allele frequencies. J Hum Genet (2011) 1.45
A candidate gene for autoimmune myasthenia gravis. Neurology (2012) 1.44
The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr (2012) 1.43
C1q and its growing family. Immunobiology (2006) 1.40
Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. Am J Hum Genet (2011) 1.39
Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res (2006) 1.39
Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (2010) 1.38
Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol (2006) 1.37
Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol (2005) 1.33
Anti-NMDA-receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. Lancet Neurol (2008) 1.32